OncoMatch/Clinical Trials/NCT03686124
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Is NCT03686124 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for refractory cancer.
Treatment: IMA203 Product · IMA203 product- flat dose · IMA203CD8 Product · Nivolumab · IMADetect® — The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available indicated standard of care treatment
must have received or not be eligible for all available indicated standard of care treatment
Cannot have received: stem cell transplantation
Prior stem cell transplantation
Cannot have received: solid organ transplantation
solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Institute · Stanford, California
- University of Miami Hospital and Clinics · Miami, Florida
- University of Chicago Medical Center · Chicago, Illinois
- Massachusetts General Hospital · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify